Search
forLearn
5 / 801 resultslearn vitamin b2
learn 18β-glycyrrhetinic acid
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn β-Glycyrrhetinic Acid
Research
5 / 1000+ results
research MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
research Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery
New drugs for heart disease may be developed from molecules secreted by stem cells.
research Reporte de caso: Presentación clínica e importancia de coinfecciones durante pandemia por COVID-19 en pacientes con neoplasias malignas
Cancer patients with COVID-19 face higher risks due to possible additional infections.
research Genotypes of Single-nucleotide polymorphisms on DENND1A in an association with polycystic ovary syndrome among Saudi Arabian females
SNP rs2479106 in the DENND1A gene may increase PCOS risk in Saudi Arabian females.
research Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review
The review found no clear link between vitamin D receptor gene variations and polycystic ovary syndrome.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Where is GT20029 already? Grrrr
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Bad news about GT20029 from Anagen Inc
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.